The Latest Breaking News from Eli Lilly

All-Pro safety Brian Dawkins comments on how NFL defenses have adjusting to the league's changing rules w/ @EdEastonJr

Missed out on giant S&P 500 winners this year like Nvidia and Eli Lilly? Don't worry: Analysts think you'll get another shot in 2025.

Eli Lilly, plus two other massive companies, just announced double-digit percentage increases in their quarterly dividend payments.

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.

Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no longer in shortage.

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its weight-loss drug.

The healthcare industry is set for growth due to the growing demand for quality treatments and ongoing progress in medical technology. Hence, investors might consider investing in healthcare stocks, Eli Lilly (LLY), Thermo Fisher Scientific (TMO), and Abbott Laboratories (ABT) for a healthy portfolio in 2025. Read more….

Construction on the facility in Kenosha County, Wis., is expected to begin next year.

Eli Lilly invests billion to boost manufacturing capabilities, expanding in Wisconsin and Indianapolis to meet growing market demand.